{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:27:54Z","timestamp":1766158074634,"version":"3.37.3"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T00:00:00Z","timestamp":1501804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada","doi-asserted-by":"publisher","award":["D7913R00016"],"award-info":[{"award-number":["D7913R00016"]}],"id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0181867","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T13:28:12Z","timestamp":1501853292000},"page":"e0181867","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9815-5921","authenticated-orcid":true,"given":"Roxana Alina","family":"Tudor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrijana","family":"D'Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"MacEachern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Kopciuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafydd Gwyn","family":"Bebb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,8,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1590\/S1806-37132015000004531","article-title":"Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer","volume":"41","author":"GL Lopes","year":"2015","journal-title":"J. Bras. Pneumol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.13032\/tjop.2052-5931.100063","article-title":"Personalized treatment of advanced non-small cell lung cancer: EGFR tyrosine kinase inhibitors as a standard of care","volume":"1","author":"A Stravodimou","year":"2013","journal-title":"J. Oncopathology"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Hansen HH: Lung cancer therapy: Annual 6. Copenhagen, Denmark, 2008, pp 1\u20138","DOI":"10.3109\/9780203092132"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5732\/cjc.011.10106","article-title":"East meets west: Ethnic differences in epidemiology and clinical behaviors of lung cancer between east Asians and Caucasians","volume":"30","author":"W Zhou","journal-title":"Chin. J. Cancer"},{"key":"ref5","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: current standards and the promise of the future","volume":"4","author":"BA Chan","year":"2015","journal-title":"Transl. Lung Cancer Res"},{"key":"ref6","first-page":"947","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"TS Mok","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small cell lung cancer with mutated EGFR","volume":"362","author":"M Maemondo","year":"2010","journal-title":"N. Engl. J. Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"T Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1634\/theoncologist.2013-0168","article-title":"Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors","volume":"18","author":"SB Goldberg","year":"2013","journal-title":"Oncologist"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0147599","article-title":"Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II study in caucasian patients (FIELT)","volume":"11","author":"J De Gr\u00e8ve","year":"2016","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"R Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bjc.2013.721","article-title":"First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study","volume":"110","author":"JY Douillard","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref13","first-page":"1","article-title":"Mechanisms of resistance to EGFR-targeted drugs: lung cancer","volume":"1","author":"F Morgillo","year":"2016","journal-title":"Br. J. Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"C Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","article-title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors","volume":"5","author":"L Huang","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref16","unstructured":"National Comprehensive Cancer Network (NCCN). Non-small cell lung cancer version 3 guideline. <comment>doi: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.1016\/0011-5029(88)90024-7\" xlink:type=\"simple\">10.1016\/0011-5029(88)90024-7<\/ext-link><\/comment>"},{"key":"ref17","first-page":"1","article-title":"Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer","volume":"9","author":"S Wang","year":"2016","journal-title":"J. Hematol. Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1200\/JCO.2015.62.1342","article-title":"Systemic therapy for stage IV non-small cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"30","author":"GA Masters","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdq189","article-title":"ESMO clinical practice guidelines for diagnosis, treatment and followup","volume":"21","author":"G D\u2019Addario","year":"2010","journal-title":"Ann. Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1200\/JCO.2010.31.8923","article-title":"American Society of Clinical Oncology Provisional Clinical Opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non\u2013small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy","volume":"29","author":"LV Keedy","year":"2011","journal-title":"J. Clin. Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial","volume":"16","author":"JC Soria","year":"2015","journal-title":"Lancet Oncol"},{"journal-title":"N. Engl. J. Med.","article-title":"Osimertinib or Platinum\u2013Pemetrexed in <italic>EGFR<\/italic> T790M\u2013Positive Lung Cancer","author":"TS Mok","key":"ref22"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4329\/wjr.v4.i4.128","article-title":"The 7th lung cancer TNM classification and staging system: Review of the changes and implications","volume":"4","author":"S Mirsadraee","year":"2012","journal-title":"World J. Radiol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref25","unstructured":"Ridgeway G, McCaffrey D, Morral A. Toolkit for weighting and analysis of nonequivalent groups. A tutorial for the twang package, 2010, pp 1\u201331"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/cncr.29397","article-title":"Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer","volume":"121","author":"PC Lo","year":"2015","journal-title":"Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cllc.2015.02.006","article-title":"Treatment of elderly patients with non-small-cell lung cancer: results of an international expert panel meeting of the Italian Association of Thoracic Oncology","volume":"16","author":"C Gridelli","year":"2015","journal-title":"Clin. Lung Cancer"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0135393","article-title":"Post-progression survival after EGFR-TKI for advanced non-small cell lung cancer harboring EGFR mutations","volume":"10","author":"Y Kogure","year":"2015","journal-title":"PLoS One"},{"key":"ref29","first-page":"4217","article-title":"Treatment after failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer","volume":"29","author":"R Maruyama","year":"2009","journal-title":"Anticancer Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/1759-7714.12236","article-title":"Subsequent treatment of epidermal growth factor receptor-tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma","volume":"6","author":"X Qiao","year":"2015","journal-title":"Thorac. Cancer"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cllc.2014.09.008","article-title":"Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: A meta-analysis","volume":"16","author":"Y Zhang","year":"2015","journal-title":"Clin. Lung Cancer"},{"key":"ref32","first-page":"1958","article-title":"Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer","volume":"33","author":"CK Lee","year":"2015","journal-title":"A Meta-Analysis. J Clin Oncol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2016.02.011","article-title":"BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study","volume":"95","author":"T Vaval\u00e0","year":"2016","journal-title":"Lung Cancer"},{"key":"ref34","first-page":"107","article-title":"Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancer","volume":"12","author":"Y Zhang","year":"2016","journal-title":"Arch Med Sci"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"MM Oken","year":"1982","journal-title":"Am J Clin Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0181867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T21:40:59Z","timestamp":1569966059000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0181867"}},"subtitle":[],"editor":[{"given":"Renato","family":"Franco","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,4]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0181867","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2017,8,4]]}}}